Dicerna Pharmaceuticals Valuation

DRNA -- USA Stock  

USD 14.43  0.09  0.63%

Dicerna Pharmaceuticals shows prevailing Real Value of $18.02 per share. The current price of the firm is $14.43. At this time the firm appears to be undervalued. This module computes value of Dicerna Pharmaceuticals from reviewing the firm fundamentals such as Operating Margin of (750.62)%, Shares Outstanding of 68.36M and Current Valuation of 656.13M as well as analyzing its technical indicators and Probability Of Bankruptcy. In general, we advise to go long with undervalued instruments and to sell out overvalued instruments since at some point assets prices and their ongoing real values will submerge.
Undervalued
September 20, 2019
14.43
Market Value
18.02
Real Value
26.24
Upside
Dicerna Pharmaceuticals is slightly risky asset. Calculation of real value of Dicerna Pharmaceuticals is based on 3 months time horizon. Increasing Dicerna Pharmaceuticals time horizon generally increases accuracy of value calculation and significantly improves predictive power of the methodology used.
Investments

Valuation Drivers Correlation

Click cells to compare fundamentals   View All Correlations
Dicerna Pharmaceuticals Valuation Data Drivers
Net Income Per Employee    Enterprise Value    Market Capitalization    

Dicerna Pharmaceuticals Market Cap

Dicerna Pharmaceuticals is rated # 4 in market capitalization category among related companies. Market capitalization of Biotechnology industry is currently estimated at about 5.51 Billion. Dicerna Pharmaceuticals retains roughly 979.6 Million in market capitalization claiming about 18% of stocks in Biotechnology industry.
Capitalization  Workforce  Revenue  Total debt  Valuation
Horizon     30 Days    Login   to change
Dicerna Pharmaceuticals is rated below average in price to book category among related companies. It is rated below average in price to earning category among related companies .

Valuation Basics

Dicerna Pharmaceuticals Enterprise Value Fundamentals

Quick Ratio3.60
Revenue Growth267.80%
Enterprise Value To Ebitda-7.44
Enterprise Value To Revenue55.25

Valuation Indicators

Dicerna Pharmaceuticals Valuation Fundamental Ratios

Additionally see Investing Opportunities. Please also try Price Ceiling Movement module to calculate and plot price ceiling movement for different equity instruments.
Search macroaxis.com